Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
March 22, 2024Cancer Research

Abstract 6042: CBP-8008: A first-in-class targeted pan-Bet protein degradation therapy using bi-specific XDC (Bi-XDC) technology for TNBC and mCRPC

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTao WangZZZhiguang ZhangGWGuitao Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e72f48b6db6435876a85a7https://doi.org/10.1158/1538-7445.am2024-6042
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 4504: Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer2024 · 1 citations
  2. 2Abstract LB360: Targeted degradation of p300 and CBP via antibody-drug conjugate in prostate cancer cells2026
  3. 3Abstract 5781: CXB-7138, A novel GSPT1/ZFP91 dual molecular glue degrader, for targeted treatment of pancreatic ductal adenocarcinoma2026
  4. 4A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.2024
  5. 5Abstract 6048: Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader2024